The need for information is a key driver of a novel alliance, to be announced today, between the APS Medical Partner Fund L.P., an affiliate of health care giant APS Healthcare Inc., and cell therapy company VivoRx Inc.

As health care payers become increasingly selective about what treatments they will cover, biotech companies have growing incentives to understand - at the front end of the drug development process- the nature of the patient population they plan to address. Such information can help them tailor drug development and clinical trial design to a highly specific patient population, improving their odds of meeting an actual market need and ending up on the payers' formularies.